<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365202">
  <stage>Registered</stage>
  <submitdate>26/10/2013</submitdate>
  <approvaldate>26/11/2013</approvaldate>
  <actrnumber>ACTRN12613001316796</actrnumber>
  <trial_identification>
    <studytitle>Endometrial preparation for cryo embryo transfer: effect of Gonadotropin Releasing Hormone Agonists (GnRHa) coupled with oestrogen and progesterone on hormonal profile and pregnancy rate</studytitle>
    <scientifictitle>The effect of endometrial preparation by pretreatment with Gonadotrophin-releasing hormone agonist (GnRha), oestrogen and progesterone, compared to endometrial preparation by oestrogen and progesterone only, on clinical pregnancy rate in infertile couples undergoing cryo embryo transfer as treatment for infertility</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil

</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Infertility</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fertility including in vitro fertilisation</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions> 
Group B (intervention group):

Patient will be treated with the GnRh-analouge, triptorelin 0.1mg/day subcutaneously  beginning in the mid luteal phase of the previous menstrual cycle and continuing till the date of embryo transfer. Full pituitary desensitization will be ensured by measuring serum estradiol on the first day of the menstrual cycle and should be less than 50 picogram /dl

Endometrial preparation  will begin  from third day of menstruation by oral Estradiol valerate 8mg/day  till endomtrium  exceeding 8.5mm, then  progesterone administration rectal suppository 400mg Am and intramuscular 100mg Pm.</interventions>
    <comparator>Group A (control group): Endometrial preparation  will begin  from third day of menstruation by oral Estradiol valerate 8mg/day   till endomtrium  exceeding 8.5mm, then  progesterone administration rectal suppository 400mg Am and intramuscular 100mg Pm .


</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>clinical pregnancy rate by
1. serum human chorionic gonadotropin (hCG) assay 14 days after embryo transfer
2. Vaginal ultrasound 2 weeks after a positive pregnancy test to detect cardiac pulsation</outcome>
      <timepoint>The primary time point (clinical pregnancy rate) is assessed 2 weeks after the frozen embryo transfer. The whole study will take a one year duration  </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>none</outcome>
      <timepoint>none</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.	Age: 35 years old or less.
2.     Infertility: primary or secondary
3.	Embryos: were frozen on day five. 
4.     Cryopreservation: closed method vitrification
5.     Laser assisted hatching prior to embryo transfer.
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>35</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.	Age above 35 years old.
2.	Abnormal uterine factor diagnosed by Vaginal sonography, Hysteroscopy or Hysterosalpingography
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>False</masking1>
    <masking2>False</masking2>
    <masking3>False</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/12/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>1/01/2015</anticipatedenddate>
    <actualenddate />
    <samplesize>140</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>Alexandria</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Elshatby University Maternity Hospital Department of Obstetrics and Gynecology</primarysponsorname>
    <primarysponsoraddress>Elshatby University Maternity Hospital
Department of Obstetrics and Gynecology
Elshatby 
PO Box; 23615
Alexandria
Egypt</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Elshatby University Maternity Hospital
Department of Obstetrics and Gynecology
</fundingname>
      <fundingaddress>Elshatby University Maternity Hospital
Department of Obstetrics and Gynecology
Elshatby 
PO Box; 23615
Alexandria
Egypt</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the work is compare artificial endometrial preparation by   oestrogen and progesterone versus pretreatment with Gonadotrophin-releasing hormone agonist (GnRha), oestrogen and progesterone for cryo embryo transfer according  to clinical pregnancy rate. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Yasser Ibrahim Orief</name>
      <address>Dr Yasser orief
El-Mosheer Ahmed Ismaiel St., 
Panorama Elshark Building 
Sidi Gaber Elshiekh tram station above HSBC bank
PO box: 21615
Alexandria
Egypt.
</address>
      <phone>+20 100 8233 121</phone>
      <fax> +20 3 544 22 64 (extension 102)</fax>
      <email>yaserorief@yahoo.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Yasser Ibrahim Orief</name>
      <address>Dr Yasser orief
El-Mosheer Ahmed Ismaiel St., 
Panorama Elshark Building 
Sidi Gaber Elshiekh tram station above HSBC bank
PO box: 21615
Alexandria
Egypt.</address>
      <phone>+20 100 8233 121</phone>
      <fax> +20 3 544 22 64 (extension 102)</fax>
      <email>yaserorief@yahoo.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Yasser Ibrahim Orief</name>
      <address>Dr Yasser orief
El-Mosheer Ahmed Ismaiel St., 
Panorama Elshark Building 
Sidi Gaber Elshiekh tram station above HSBC bank
PO box: 21615
Alexandria
Egypt.
</address>
      <phone>+20 100 8233 121</phone>
      <fax> +20 3 544 22 64 (extension 102)</fax>
      <email>yaserorief@yahoo.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Yasser Ibrahim Orief</name>
      <address>El-Mosheer Ahmed Ismaiel St., 
Panorama Elshark Building 
Sidi Gaber Elshiekh tram station above HSBC bank
PO box: 21615
Alexandria
Egypt.</address>
      <phone>+20 100 8233 121</phone>
      <fax> +20 3 544 22 64 (extension 102)</fax>
      <email>yaserorief@yahoo.com</email>
      <country>Egypt</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>